Angiostatin endostatin gene therapy - Genetix Pharmaceuticals

Drug Profile

Angiostatin endostatin gene therapy - Genetix Pharmaceuticals

Alternative Names: Genostatin

Latest Information Update: 08 Jul 2003

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Genetix Pharmaceuticals
  • Class Gene therapies
  • Mechanism of Action Angiogenesis inhibitors; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 08 Jul 2003 Discontinued - Preclinical for Cancer in USA (Parenteral)
  • 07 Jan 2002 No-Development-Reported for Cancer in USA (Parenteral)
  • 21 Apr 1998 Preclinical development for Cancer in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top